---
title: "CKLIFE SCIENCES issued a profit warning, expecting a mid-term loss attributable to shareholders of approximately HKD 150 million, a year-on-year turnaround from profit to loss"
description: "According to the announcement from CKLIFE SCIENCES, the group expects to incur a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder pr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250966881.md"
published_at: "2025-07-31T10:15:03.000Z"
---

# CKLIFE SCIENCES issued a profit warning, expecting a mid-term loss attributable to shareholders of approximately HKD 150 million, a year-on-year turnaround from profit to loss

> According to the announcement from CKLIFE SCIENCES, the group expects to incur a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder profit of HKD 1 million in the same period of 2024. The shift from profit to loss is attributed to the company's earlier decision to increase R&D investment. Overall, the group's operations have remained stable during the reporting period and up to the date of this announcement

According to the announcement from CKLIFE SCIENCES (00775), the group expects to incur a shareholder's attributable loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder's attributable profit of HKD 1 million for the same period in 2024. The shift from profit to loss is attributed to the company's earlier decision to increase research and development investment. Overall, the group's operations have remained stable during the reporting period and up to the date of this announcement

### Related Stocks

- [00775.HK - CKLIFE SCIENCES](https://longbridge.com/en/quote/00775.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| RISING CANCER RATES AND A PROMISING CANCER TREATMENT | The rising cancer rates among younger Americans, highlighted by the death of actor James Van Der Beek from colorectal ca | [Link](https://longbridge.com/en/news/276298689.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/en/news/276393466.md) |
| Singapore launches guidelines for family doctors to manage patients’ menopause | Singapore has launched its first set of Guidelines on Management of the Menopause Transition to aid healthcare professio | [Link](https://longbridge.com/en/news/276430476.md) |
| Campus vaccine strategies put to test by rising measles cases | New outbreaks of measles in the U.S. are prompting colleges to reconsider their vaccine strategies. The University of Wi | [Link](https://longbridge.com/en/news/276325311.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.